Introduction. High basal renin-angiotensin system (RAS) activity is associated with increased risk of severe hypoglycaemia in type 1 diabetes. We tested whether this might be explained by more pronounced cognitive dysfunction during hypoglycaemia in patients with high RAS activity than in patients with low RAS activity. Materials and methods. Nine patients with type 1 diabetes and high and nine with low RAS activity were subjected to hypoglycaemia and euglycaemia in a cross-over study using an intravenous insulin infusion protocol. Cognitive function, electroencephalography, auditory evoked potentials and hypoglycaemic symptoms were recorded. Results. At a hypoglycaemic nadir of 2.2 (SD 0.3) mmol/L the high RAS group displayed significant deterioration in cognitive performance during hypoglycaemia in the three most complex reaction time tasks. In the low RAS group, hypoglycaemia led to cognitive dysfunction in only one reaction time task. The high RAS group reported lower symptom scores during hypoglycaemia than the low RAS group, suggesting poorer hypoglycaemia awareness. Conclusion. High RAS activity is associated with increased cognitive dysfunction and blunted symptoms during mild hypoglycaemia compared to low RAS activity. This may explain why high RAS activity is a risk factor for severe hypoglycaemia in type 1 diabetes.
Introduction
Hypoglycaemia is a major limitation of insulin therapy in type 1 diabetes. 1 Severe hypoglycaemia characterised by significant cognitive dysfunction and consequently dependence upon assistance from other persons is frequent in -and feared by -patients with type 1 diabetes. [1] [2] [3] [4] A minor subset of patients are prone to recurrent severe hypoglycaemia. 2 We, and others, have reported a clinically significant association between high spontaneous activity of the reninangiotensin system (RAS) and elevated rate of severe hypoglycaemia in type 1 diabetes. [5] [6] [7] [8] [9] Thus, three components of RAS are independently associated with increased risk of severe hypoglycaemia: high angiotensin-converting enzyme (ACE) activity [5] [6] [7] [8] (which is partially genetically determined, mainly by the insertion/deletion (I/D) polymorphism 10 ), high plasma angiotensinogen concentration, 11 and presence of the A-allele of the angiotensin II type 2 receptor (AT 2 receptor) genotype 1675 G/A single nucleotide polymorphism. 11 The mechanism of the association is unknown. Recently, we reported that healthy subjects with high ACE activity are more susceptible to cognitive dysfunction and report higher symptom scores during moderate hypoglycaemia than those with low ACE activity, whereas key hormonal counter-regulatory responses and concentrations of substrates did not differ between the groups. 12 The aim of this study was to re-examine this finding in people with type 1 diabetes with low or high spontaneous activity in RAS based on the three aforementioned components of RAS.
Methods

Subjects
Nine subjects with high RAS activity and nine subjects with low RAS activity were selected from a group of 260 outpatients with type 1 diabetes. Selection according to RAS groups was based on three factors, all independently contributing to risk of hypoglycaemia: ACE activity, [5] [6] [7] [8] concentration of angiotensinogen, 11 and the AT 2 receptor genotype 1675 polymorphism. 11 ACE activity scored 1-4 points according to quartiles (lowest activity quartile = 1 point), plasma concentration of angiotensinogen, likewise, scored 1-4 points Cognitive performance, symptoms and counterregulation during hypoglycaemia in patients with type 1 diabetes and high or low renin-angiotensin system activity (lowest concentration quartile = 1 point), and AT 2 receptor 1675 single nucleotide polymorphism genotype GG, AG, and AA scored 1, 2, and 3 points, respectively, as previously described. 13 The subjects were originally included in an observational study of the association between risk of severe hypoglycaemia and ACE activity and ACE genotype. 6 Criteria for inclusion and exclusion are described in detail by Pedersen-Bjergaard et al. elsewhere. 6 Importantly, no subjects were treated with ACE inhibitors or angiotensin II receptor antagonists, since these drugs interfere with naturally occurring RAS activity. No subjects were treated with strong analgesics, which could interfere with cognitive function. None of the subjects had diabetic nephropathy, hypertension, macrovascular disease, or heart failure. The two groups were selected primarily to represent the extremes of RAS activity. Because hypoglycaemic defences including hormonal counter-regulatory and symptom responses are heavily modified along the course of diabetes, 14 they were sought to be matched in terms of diabetes duration. The two groups did not differ in baseline characteristics. However, patients in the high RAS group have had significantly more episodes of severe hypoglycaemia in the previous year, and there was a trend towards a higher prevalence of impaired hypoglycaemia awareness or unawareness, according to a validated classification system, 2,15 than in the low RAS group (table 1) . It was not possible to circumvent this skewness without blunting the differences in RAS characteristics significantly. The Regional Ethics Committee approved the study. Written informed consent was obtained from all subjects.
Design
The study was a single-blinded, controlled, crossover study. Hypoglycaemia was induced by a standardised intravenous insulin infusion. Each subject was studied at two occasions separated by at least four weeks: during hypoglycaemia and at a maintained baseline glycaemic level (control study) (figure 1).
Experimental protocol
Week before experiment Subjects were instructed to live and eat as normal as possible and to avoid any rigorous exercise and use of alcohol or psychoactive drugs in the week preceding the experiment.
Day before experiment
In the evening before the experiment, subjects were re-informed about the experimental protocol and a continuous glucose monitoring device (CGMS, Medtronic Minimed, Northridge, California, USA) was mounted in order to monitor glycaemic excursions during the night before the experiment.
Day of experiment
Subjects arrived at 7.30 a.m. in the laboratory after an overnight fast. Data from the CGMS were 16 the test was performed once to accustom the subjects to the procedure. The experiment was carried out in a cyclic manner with a total of six cycles: two baseline cycles, two cycles with hypoglycaemia or maintained glycaemic level and two post-experiment cycles. Each cycle began with bedside blood glucose measurement followed by 3-5 minutes of rest for background EEG recording with eyes closed. Subsequently, blood pressure and pulse were measured, the Alzheimer Quick Test (AQT) was performed, and auditory evoked potentials (AEP) were recorded. Venous blood was then drawn for measurement of plasma glucose, substrates, counter-regulatory hormones and RAS hormones. Then the CalCAP test was performed and hypoglycaemic symptoms were scored (figure 1). Additional bedside blood glucose concentrations for monitoring were measured at 10-minute intervals. 
Intravenous insulin infusions
Hypoglycaemia
After the second cycle, 500% of the subject's insulin morning-dose (human insulin, Actrapid, Novo Nordisk, Bagsvaerd, Denmark) mixed with 500 ml of isotonic saline was infused intravenously (100 ml/h) until the bedside blood glucose was below 5 mmol/L, after which the infusion was stopped. If the desired blood glucose level was not achieved, the insulin infusion was restarted with a lower, customised rate. In pilot studies, this dosage scheme resulted in stable hypoglycaemia with nadir in the range between 2.0-2.5 mmol/L, which was the hypoglycaemic target in this study. Bedside monitoring of blood glucose level during experiments was done every 10 minutes. After the fourth cycle, the subject drank 0.5 L of apple juice in order to re-establish a normal glucose level.
Control study
To stabilise the glucose level, human insulin and glucose were infused intravenously throughout the study. After the second cycle, we infused 500 ml of 10% glucose (50 ml/h), and if the subject's blood glucose concentration at the end of the second cycle was 3.5-4.9 mmol/L, 6 IU of insulin was added to the glucose infusion. If the blood glucose was 5-10 mmol/L, we added 10 IU of insulin, and if the blood glucose was above 10 mmol/L, 18 IU of human insulin was added.
Hypoglycaemia symptom scoring
Hypoglycaemic symptoms were assessed with The Edinburgh Hypoglycaemia Scale, which is a questionnaire in which the subjects must indicate the severity of pre-defined hypoglycaemic symptoms on a scale from one to seven. 17
Cognitive function tests
CalCAP
The Danish version of the abbreviated CalCaP test (EN Miller, California Cognitive Assessment Package, Norland Software, Los Angeles, 1990) runs on a computer screen and consists of four different reaction time tasks with increasing complexity: 1) a simple reaction time test where subjects must strike a key when a number is presented; 2) a choice reaction task with reaction to a specific number; 3) a choice reaction task with reaction to two identical numbers in a sequence; and 4) a choice reaction test with reaction to two numbers in a sequence (increasing order). The two latter tests include the use of working memory. We calculated the individual mean reaction times (MRT) for each test (MRT1, MRT2, MRT3, and MRT4) in milliseconds and the error rates (ER = (false positive + false negative reactions) / total number of tasks) for the three choice reaction tests (ER2, ER3, and ER4).
AQT
The AQT measures cognitive and perceptual speed and has been shown to assess function of the parietal lobe. 18, 19 In this study, the last section of part A was used. Subjects must name 40 objects (circle, line, square and triangle) in different colours (black, blue, red and yellow), for example red square, blue triangle, etc. Due to its design, the test can be used across linguistic and cultural domains. The time to perform the combined task was measured in seconds.
Neurophysiological tests
EEG
Continuous 20-channel EEG was recorded digitally (200-Hz sampling rate) throughout the experiment. Data were filtered by a first-order 0.53-Hz low-cut filter and a first-order 70-Hz high-cut filter. For each cycle, the EEG from the 3-5-minute resting period with eyes closed was extracted. Two derivations (C3-P3 and C4-P4) were selected for power spectral analysis. Power spectral analysis was performed on pre-emphasised signals (first-order high-pass filter with 4.5-Hz cut-off frequency) using FFT on 2-second epochs (~400 samples, giving 0.5-Hz resolution in the FFT power spectrum). If a peak in the power spectrum could be identified in the range 7-13 Hz, it was extracted as representative for the alpha frequency. For cycle 1+2 together and for each of the consecutive cycles, mean values were calculated for each patient and averaged for the left and right side.
Visual assessment of the EEG was performed on all the 3-5-minute resting periods. Two experienced clinical neurophysiologists specialised in clinical EEG-reading performed the visual assessment.
AEP
AEP were obtained by an auditive stimulation paradigm consisting of more than 500 stimuli delivered with an attended:unattended ear ratio of 1:4. In order to maintain attention, subjects were asked to count the number of stimuli given to the attended ear. Two different tones were used: 700 Hz (attended ear) and 350 Hz (unattended ear). The duration of each stimulus was 100 msec and the inter-stimulus interval was 715 msec. The AEP sweeps were extracted from the continuous EEG recordings based on trigger pulses stored on auxiliary channels on the EEG recorder. Evoked potentials are expressed as difference in amplitude of time-averaged (230-255msec latency) potentials between attended and unattended response (odd-ball response). The difference between these amplitudes was compared within subjects between the hypoglycaemic and the control experiment.
Biochemical analyses
Bedside capillary blood glucose measurements used for monitoring during the experiments were done by a HemoCue Analyzer (HemoCue AB, Sweden). Plasma glucose concentrations used for evaluation of the hypoglycaemic challenge were measured enzymatically (COBAS INTEGRA, Roche, Basel, Switzerland). Plasma glucagon concentrations were measured with a radioimmunoassay directed against the C-terminus of the glucagon molecule (antibody code no. 4305), which mainly measures glucagon of pancreatic origin. 20 Catecholamines were determined by HPLC with fluorometric detection. 21 Serum growth hormone concentration was determined with a commercial fluorometric method (Delfia, Wallac, Finland) using two monoclonal antibodies against two separate antigenic determinants on the growth hormone molecule. Renin and prorenin were determined by in-house radioimmunoassays of generated angiotensin I. 22 Angiotensinogen was determined as the maximal quantity of angiotensin I generated during incubation of plasma in the presence of excess recombinant human renin. 23 Angiotensin II was determined after SepPak extraction from plasma with an inhouse radioimmunoassay. 24 The AT 2 receptor 1675G→A polymorphism was determined by polymerase chain reaction as previously described. 25 ACE activity was determined as reported by Pedersen-Bjergaard et al. 5 26 and differences in response between groups were analysed by unpaired t-tests. A p value < 0.05 (two-sided) was considered significant. Calculations were performed using statistical software (SPSS, version 13.0 for Windows). 
Day of maintained blood glucose level
Plasma glucose (figure 2), insulin doses and insulin concentrations did not differ significantly between RAS groups (data regarding insulin not shown).
Hypoglycaemic symptoms
At baseline, there was no difference in symptom scores between the groups (table 2). In the high RAS group, autonomic and neuroglycopenic symptom scores during hypoglycaemia did not differ from baseline scores (table 3 and figure 3 ).
In the low RAS group, neuroglycopenic symptom scores were significantly higher during hypoglycaemia compared to baseline and autonomic symptom scores tended to be higher at hypoglycaemia than at baseline. Placebo-corrected AUC values for both autonomic symptoms and neuroglycopenic symptoms were significantly higher in the low RAS group than in the high RAS group (table 3) . 3 and figure 3 ). Visual assessment did not identify any systematic changes in the background activity between groups.
AEP
The time-averaged potentials of attended sweeps minus unattended sweeps (230-255 msec) at baseline, during hypoglycaemia and after normalisation of plasma glucose were 3.92 μV, 3.63 μV, and 3.56 μV in the low ACE group, and 2.01 μV, 1.36 μV, and 0.57 μV in the high RAS group. There were no significant changes during or after hypoglycaemia in either group. However, there was a consistent difference between RAS groups (p<0.05 at baseline, p<0.05 at hypoglycaemia, and p<0.001 after hypoglycaemia).
Hormonal counter-regulation
At baseline, counter-regulatory hormone concentrations did not differ between the RAS groups (table 2) . A significant glucagon response during hypoglycaemia was observed in the low RAS group, but not in the high RAS group (table 3 and  figure 6 ). The glucagon response in the low RAS group tended to be higher than in the high RAS group. Adrenaline concentrations increased significantly during hypoglycaemia in both groups and the response tended to be greater in the low RAS group. Noradrenaline concentrations tended to rise in the low RAS group but not in the high RAS group. Similar cortisol responses during hypoglycaemia were observed in the RAS groups. A significant growth hormone response was apparent in the high RAS group, whereas the response in the low RAS group did not reach statistical significance. The difference between the RAS groups was not significant.
Substrates
There were no differences between RAS groups at baseline (table 2) . Lactate and free fatty acid concentrations rose in the low RAS group but not in the high RAS group, but with no difference between the groups (table 3 and figure 7) . The concentration of alanine declined during hypoglycaemia in the high RAS group, but in the low RAS group alanine only tended to decline. There was no difference between RAS groups. Concentrations of beta-hydroxybutyrate and glycerol were unchanged during hypoglycaemia.
RAS activation
Plasma renin activity increased in both RAS groups during hypoglycaemia without any difference between the groups (table 3) . There were no significant alterations in angiotensinogen, angiotensin II and aldosterone during hypoglycaemia.
Cardiovascular responses
At baseline, there was no difference in heart rate and mean arterial blood pressure between RAS groups (table 2) . Heart rate tended to increase during hypoglycaemia in both groups, but there was no difference between RAS groups (table 3) . Mean arterial blood pressure AUC did not change during hypoglycaemia in the two RAS groups and there was no difference between groups.
Counter-regulation, cognitive performance and hypoglycaemic symptoms according to awareness classification
Because the distribution of hypoglycaemia awareness tended to differ between the two RAS groups, we made a post hoc analysis exploring the impact of awareness on responses to hypoglycaemia. This was done by dividing the subjects in two groups with normal (n=6) or impaired Paper SAGE Publications 2009 Los Angeles, London, New Delhi and Singapore awareness (impaired awareness or unawareness (n=12)). Subjects with normal awareness had significant higher symptom scores during hypoglycaemia and approximately a threefold higher adrenaline response. However, this difference only tended towards significance. In contrast, there was no systematic difference between the two awareness groups' cognitive performances as measured by the CalCaP test (table 4) .
Discussion
This study shows that patients with type 1 diabetes with high RAS activity develop more pronounced cognitive dysfunction during mild hypoglycaemia than patients with low RAS activity do. The prolongation of reaction time by approximately 100 msec in the most complex tasks is comparable to the finding in non-diabetic subjects with high ACE activity. 12 The cognitive decline in the high RAS group was accompanied by a clinically relevant decline of the dominant alpha frequency in the EEG recordings during hypoglycaemia. This shift from normal alpha activity is also seen during development of sleep or precoma. The present findings are in accordance with the previously reported association of elevated ACE or RAS activity and risk of episodes of severe hypoglycaemia in type 1 diabetes, [5] [6] [7] [8] [9] that are characterised by severely impaired cognitive function interrupting selfcare. The trend towards a difference between our groups in terms of hypoglycaemia awareness, which was not possible to rule out without jeopardising the discrimination in RAS activity, is a potential confounding factor. However, the post hoc analysis showed that there was no relationship between the state of hypoglycaemia awareness and cognitive performance during hypoglycaemia.
Subjects with high RAS activity reported lower autonomic and neuroglycopenic symptom scores during hypoglycaemia than did subjects with 27 This association is confirmed by the post hoc analysis according to awareness in the present study. The different state of awareness in the two RAS groups at baseline was not explained by differences in duration of diabetes or glycaemic control as judged by HbA1c. A more likely explanation is that subjects with high RAS activity are more prone towards development of impaired awareness due to their more frequent exposure to significant hypoglycaemia. This is supported by an association between high RAS activity and impaired awareness of hypoglycaemia in our cohort study. 11 The hypoglycaemic stimulus generated significant counter-regulatory hormonal responses in both RAS groups with no significant in-between group differences in any hormone responses. However, those with low RAS activity produced more significant glucagon and catecholamine responses, whereas the high RAS group produced a more significant growth hormone response. The cortisol response was similar in the two groups. In our previous study in healthy subjects with high or low serum ACE activity, there was no difference between the groups in terms of glucagon and catecholamine responses, 12 but there was a similar trend towards a more pronounced delayed growth hormone response in the high ACE group as in the present study. This apparent discrepancy between the glucagon and catecholamine responses between the healthy subjects and the patients with type 1 diabetes may well be explained by the fact that glucagon and catecholamine responses to hypoglycaemia are blunted in type 1 diabetes, 14 and that the catecholamine responses are linked to awareness as discussed above. More pronounced alterations in circulating substrate concentrations were observed in the low RAS group, suggesting that the low RAS group to a greater extent compensates by switching to alternative substrates. Thus, a greater free fatty acid release was observed, 
Figure 7
Plasma concentrations of circulating substrates (lactate, beta-hydroxybutyrate, free fatty acids, glycerol, alanine) during experiments. Shown are mean (SEM) responses (placebo-corrected Δ-values). Average of cycle 1 and 2 is reference (= 0). p values: onesample t-test of AUC. AUC = area under curve; n.s. = non-significant; RAS = renin-angiotensin system. probably driven by the more pronounced catecholamine response. Furthermore, a significant lactate response was only present in the low RAS group. This may be beneficial for preservation of cognitive function during hypoglycaemia because it has been shown that infusion of lactate conserves human brain function during hypoglycaemia. 28 The pattern of the responses in circulating substrate concentrations according to RAS activity was the same as in our study on healthy subjects. 12 The physiological or neurocellular mechanisms mediating the detrimental effect of high RAS activity on cognitive function during mild hypoglycaemia are unknown, but the finding is supported by several previous observations. Thus, numerous studies show that downregulation of RAS by inhibition of ACE or blocking of angiotensin II receptors (mainly angiotensin II type 1 receptor (AT 1 receptor)) enhances cognitive performance in animals and in man in the setting of adequate substrate supply (reviewed by von Bohlen und Halbach and Albrecht 29 and Gard 30 ). Likewise, in conditions with insufficient or interrupted substrate availability, low RAS activity or AT 1 receptor blockade is associated with preservation of neuronal metabolism and function. Thus, knockout of the AT 1 receptor gene is associated with conservation of ATP in neurones exposed to ischaemia, suggesting either reduced or more efficient metabolism. 31 We used an intravenous insulin infusion protocol without supplementary exogenous glucose supply. The resulting hypoglycaemic stimulus may be more variable compared to conventional glucose clamp techniques. The strength of our approach is that the insulin dose is minimised resulting in a reduced risk of supraphysiologic insulin effects in the brain, 32, 33 and that all responses are the result of endogenous substrate fluxes. Importantly, the differences in cognitive performance, hypoglycaemic symptoms and response patterns of counterregulatory hormones and substrates between the RAS groups occurred despite a comparable insulin dose, resulting in similar insulin concentrations and a similar hypoglycaemic challenge in the two RAS groups.
Journal
Clearly, the results of our study need to be confirmed. However, the results are intriguing and of potential importance for the large proportion of patients with type 1 diabetes who are prone to recurrent severe hypoglycaemia. Studies of the effect of pharmacological RAS inhibition by renin blockers, ACE inhibitors, or angiotensin II receptor blockers on cognitive function during experimental Table 4 Responses to hypoglycaemia (placebo-corrected area under curve (AUC day of hypoglycaemia -AUC day of control )) according to hypoglycaemia awareness category. 
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